does glp-1 help fatty liver Frontiers 🩺 𝐅𝐚𝐭𝐭𝐲 𝐋𝐢𝐯𝐞𝐫 𝐂𝐚𝐧 𝐁𝐞

Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs

Sone, Y

Affected individuals are typically characterised by lipoatrophic diabetes, insulin resistance and hepatic steatosis ( Agonists of the glucagon-like peptide-1 receptor (GLP-1R) deliver significant beneficial effects both in treating type 2 diabetes and obesity ( Reports of the effects of GLP-1R agonists in individuals with inherited lipodystrophies are currently limited to only 3 case studies, and these examine FPLD but not CGL patients ( Here we used a well validated Bscl2 -null (seipin knockout) mouse model of CGL type 2 (CGL2) to examine the effectiveness of a GLP-1R agonist, in treating lipoatrophic diabetes, hepatic steatosis and hyperphagia in CGL to inform the adoption of this class of drugs for individuals with lipodystrophy

Therefore, this review presents the triangle relationship of obesity, DM as well as cancer development and elucidates the treatment of overweight-associated T2DM with semaglutide, focusing on the question of whether the development of these conditions can be combated or if any severe side effects should be considered of this therapy

The state insurer implemented coverage restrictions that aligned with the broader BCBS trend, removing weight management as a standalone covered indication